NCT03660930View on ClinicalTrials.gov

Nab-Sirolimus and Pazopanib Hydrochloride in Treating Patients With Advanced Nonadipocytic Soft Tissue Sarcomas

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

April 1, 2019

Primary Completion Date

November 17, 2022

Study Completion Date

July 31, 2024

Conditions
Advanced Soft Tissue SarcomaLocally Advanced Soft Tissue SarcomaMetastatic Soft Tissue Sarcoma
Interventions
DRUG

Sirolimus Albumin-bound Nanoparticles

Given IV

DRUG

Pazopanib hydrochloride

Given PO

Trial Locations (1)

98109

Fred Hutch/University of Washington Cancer Consortium, Seattle

Sponsors

Collaborators (1)

Aadi Bioscience, Inc.
All Listed Sponsors
collaborator

Aadi Bioscience, Inc.

INDUSTRY

lead

University of Washington

OTHER